Barclays Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $66
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweight rating and announces Price Target of $66.
Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweight rating and announces Price Target of $66.